Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
June 2020
-
In The News
Breaking Through The Glass Ceiling - A Spring For Women In Artificial Intelligence
-
In The News
The Curious Advantage: Curiosity – The CEO and The Chief People and Organization Officer Perspective
Vas Narasimhan, CEO of Novartis and Steven Baert, Novartis’ Chief People and Organization Officer join the authors of The Curious Advantage Simon Brown, Paul Ashcroft and Garrick Jones, to… -
Media Release
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19… -
Streamlining systems to respond to COVID-19
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
-
Featured News
World Sickle Cell Day 2020
Standing by people with sickle cell disease and their families
-
Media Release
Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients… -
Key Release
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial… -
Featured News
Day of the African Child 2020
COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.
-
Statement
Standing for Racial Equity and Justice as One Novartis
-
Media Release
US FDA approves updated Novartis Beovu® label, to include additional safety information
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The… -
Media Release
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving… -
Media Release
Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA…
Pagination
- ‹ Previous page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- …
- 154
- › Next page
Test disclaimer...!!!